Figure 4

MM patient 2 profile schematic. (A) The key signaling pathways and crosstalk relevant for MM patient 1 are presented. This profile exhibits a chromosome 11:14 translocation, losses in chromosomes X and 9, amplification of CCND1 and a knockdown of tumor suppressors RXRA, TGFBR1, TJP2 and TSC1. The combination of trametinib (ERK inhibitor) and sirolimus (mTOR1 inhibitor) were predicted to demonstrate optimal efficacy. The predictive (B) vs. experimental (C) results regarding the impact of sirolimus and trametinib individually and in combination on relative cell growth. (D) Western blot of non-treated (NT), trametinib (T), sirolimus (S) and combination (S/T) for the biomarker cyclin D1 and CDKN1A. Actin serves as a loading control.